Bayer flags major Phase III results for stroke prevention drug asundexian
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
This combination works to break down rough patches, improve moisture retention, and enhance overall skin texture
Integrated eCOA technology and rater training aim to reduce variability and strengthen ClinRO outcomes
ICMR-led consultation calls for stricter HFSS regulations, nutrition literacy, and healthier food environments
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
Research by NITI Aayog and All India Institute of Medical Sciences has shown that at least 30% of trauma deaths are linked to delays in emergency response
The CE Mark builds on the company’s ISO 13485 certification, further strengthening confidence in the platform's safety, quality and performance
Collaboration aims to align hospital staff learning with NABH 6th Edition standards, patient safety, and measurable quality outcomes
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
The goal is to better support drug developers as programs move from laboratory research into clinical trials
Subscribe To Our Newsletter & Stay Updated